GeneDx Q1 2026 misses targets; lower-margin genomic tests slow growth, but turnaround potential remains.

GeneDx Holdings Corp. reported Q1 2026 results that fell short of expectations, leading to a lowered annual guidance. The main reasons were a shift in product mix towards faster-growing but lower-priced and lower-margin genomic testing, which impacted blended test pricing and delayed sales cycles. Despite these challenges, the company's core business fundamentals remain solid, presenting a high-risk, high-reward opportunity for investors looking for a turnaround. The company specializes in advanced exome and genome diagnostic testing using its proprietary GeneDx Infinity dataset for superior interpretation.